ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Neuraminidase (NA)

Neuraminidase (NA)

概要

Name:Neuraminidase
Target Synonym:Neuraminidase
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

NEE-MY2069-MALS-HPLC
Neuraminidase (NA) MALS images

The purity of Monoclonal Anti-Influenza A virus NA (H1N1) (Victoria/2570/2019) Antibody, Human IgG1 (8E5) (Cat. No. NEE-MY2069) is more than 90% and the molecular weight of this protein is around 135-160 kDa verified by SEC-MALS.

NEE-MY2069-ELISA
 Neuraminidase (NA) ELISA

Immobilized Influenza A [Victoria/2570/2019(H1N1)] Neuraminidase (NA) Protein, His Tag (Cat. No. NEE-V524e) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Influenza A virus NA (H1N1) (Victoria/2570/2019) Antibody, Human IgG1 (8E5) (Cat. No. NEE-MY2069) with a linear range of 0.3-5 ng/mL (QC tested).

Synonym Name

NA,Neuraminidase

Background

Neuraminidase (NA) and hemagglutinin (HA) are major membrane glycoproteins found on the surface of influenza virus. Hemagglutinin binds to the sialic acid-containing receptors on the surface of host cells during initial infection and at the end of an infectious cycle. Neuraminidase, on the other hand, cleaves the HA-sialic acid bondage from the newly formed virions and the host cell receptors during budding. Neuraminidase thus is described as a receptor-destroying enzyme which facilitates virus release and efficient spread of the progeny virus from cell to cell.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Laninamivir Octanoate Hydrate CS-8958; R-118958 Approved Daiichi Sankyo Co Ltd Inavir Japan Influenza B virus infection; Influenza A virus infections Daiichi Sankyo Co Ltd 2010-09-10 Influenza A virus infections; Influenza, Human; Influenza B virus infection Details
Peramivir Hydrate JNJ-2; BCX-1812; S-021812; RWJ-270201 Approved Biocryst Pharmaceuticals Inc 力纬, Alpivab, Rapivab, Rapiacta, Peramiflu United States Influenza, Human Biocryst Pharmaceuticals Inc 2010-01-13 Cough; Headache; Myalgia; Influenza A virus infections; Fatigue; Musculoskeletal Pain; Influenza, Human; Fever; Nasal Obstruction; Arthralgia; Influenza B virus infection; Pharyngitis Details
Zanamivir GG-167; GR-121167; GR-121167X; 4-Guanidino-Neu5Ac2en Approved Glaxosmithkline Plc 依乐韦, Relenza EU Influenza, Human Glaxosmithkline Trading Services Ltd 1999-07-26 Orthomyxoviridae Infections; Diabetes Mellitus, Type 2; Influenza, Human; Arthralgia; Dengue Details
Oseltamivir Phosphate Ro-64-0796; GS-4104; RO-640796; GS-4104-002; EN-241104; RO-640796/002; GS-4104/002 Approved F. Hoffmann-La Roche Ltd Tamiflu, Hanmi Flu, 达菲 EU Influenza, Human Roche Registration Gmbh 1999-09-21 Purpura, Thrombocytopenic, Idiopathic; Influenza A virus infections; Influenza, Human; Influenza in Birds; Obesity; Kidney Failure, Chronic Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
Oseltamivir/Pimodivir Phase 1 Clinical Johnson & Johnson Influenza A virus infections Details
HNC042 HNC-042 Phase 1 Clinical Guangzhou Henovcom Bioscience Co Ltd Influenza A virus infections; Influenza, Human; Influenza B virus infection Details
AV-5080 AV-5080 Phase 3 Clinical Viriom Inc Influenza, Human Details

This web search service is supported by Google Inc.

totopphone